The Center for Drug Evaluation (CDE), a key component of China’s National Medical Products Administration (NMPA), is currently soliciting public feedback on the 84th batch of chemical generic reference preparations. The consultation period will remain open until July 10, 2024.
In this batch, the list comprises 27 new specifications that are being considered for the first time, along with 64 additional specifications that have been appended to the existing registry. However, 35 specifications have not met the review criteria. The reasons for their non-inclusion are varied and include the absence of reference preparation status and an inability to demonstrate significant clinical value.- Flcube.com
